(f) if so. the details thereof?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (f) The prices of bulk drugs are fixed by this Ministry on the basis of cost-cum-technical study conducted by BICP and their examination in this Department. Government has received several reports from BICP in connection with cost-cum-technical study of bulk drugs and the prices have been fixed after examination of report of BICP which have been notified in the Gazette of India from time to time. The BICP reports are input for our decision making in the process of price fixation. These reports are confidential in nature. In regard to other details asked for, the information is too voluminous and the time and efforts required for compiling the information will not be commensurate with the results likely to be achieved.

Representations of M.Ps. against the price decontrol of Glybenclamide

1669. SHRIMATI PRATIBHA SINGH: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 1656 given in the Rajya Sabha on the 1st August, 1991 and state:

(a) whether it is a fact that Government have received a number of representations from Members of Parliament against the price decontrol of Glybenclamide;

(b) if so, when each representation was received and what action has been taken on each;

(c) whether it is also a fact that sales turnover was one of the criteria of price decontrol;

(d) if so, what was the source of data of sales turnover and what are the basis of vertification of annual sales turnover of Glybenclamide;

(e) whether it is a fact that formulations of Glybenclamide has a monopoly of one company; and

(f) if so, names of the company and what is the market share enjoyed by that company?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) and (b) All such representations as have been received from Members of Parliament against the price decontrol of Glybenclamide has been considered by the Standing Committee. The matter is now under examination of the Government.

(c) Yes, Sir.

(d) The decontrol of bulk drug Glybenclamide is not based on sales turnover. The basis on which this drug has been price decontrolled is contained in the supplementary report of the Kelkar Committee, copy of which is available in the Parliament Library.

(e) and (f) M/s. Hoechst India Limited are the major formulator of bulk drug Glybenclamide. Market share of companies with regard to formulations are not monitored.

Procedures adopted by BICP

1670. KUMARI SAYEEDA KHATUN: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 1654 given in the Rajya Sabha on the 1st August, 1991 and state:

(a) what is the procedure adopted by BICP to work out the prices of formulations;

(b) what is the period taken after the notification/fixation of prices of bulk drugs;

(c) what are the names of drugs based on which prices of finished medicines have not been notified within three months of the fixation of prices of bulk drugs;

(d) whether implementation of the notified prices can be held in abeyance on the ground that it requires some clarifications;